Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 8, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific equity transactions and does not contain financial performance data.
Material Changes
- Employee Share Option Plan: On June 7, 2005, the GlaxoSmithKline Employee Trust transferred 24,908 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Savings Plan: On June 3, 2005, the GlaxoSmithKline US Retirement Savings Plan experienced a movement in holdings, increasing from 18,260,572 to 18,318,099 Ordinary Share ADRs at an average price of $50.02.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. It strictly details administrative changes in share ownership related to employee benefit plans.
Key Facts for Investor Verification
- Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) have interests in the shares held by the GSK Trust.
- Two directors (Dr J P Garnier and Dr T Yamada) have potential interests in the shares held by the US Retirement Savings Plan.
- The reported ADR price of $50.02 reflects the average price of the fund movement on June 3, 2005, not necessarily the closing market price.